MERS快有治了？ 首次动物实验成功

序道

      中东呼吸综合征（MERS）近来在韩国的传播态势牵动人心。自从3年前在沙特阿拉伯发现这种疾病以来，还一直没有能治它的有效药物。现在终于传出好消息，美国马里兰大学等机构的研究人员29日在《国家科学院学报》上报告说，研发出了两种抗体，首次在动物实验中成功证明能用它们治疗感染了MERS的实验鼠。做出本次发现的关键人物马修说：“虽然这项研究还处于早期，但它真正有潜力帮助患者。”（来源：北京晚报）

序道

ipsvirus 发表于 2015-7-2 10:27
针对MERS-CoV的S蛋白的受体结合区（RBD）之前已经报到筛选到了很多抗体，但都是在细胞水平上进行抗病毒效价 ...

不过 加上你发的回复 这篇文章就算很完美了啊

ipsvirus

针对MERS-CoV的S蛋白的受体结合区（RBD）之前已经报到筛选到了很多抗体，但都是在细胞水平上进行抗病毒效价评估。本文的突破是在DPP4转基因小鼠上进行了抗体保护实验，得到了理想的数据。

真要实现治疗MERS-CoV还是要找到特异性药物或者高效疫苗。抗体治疗适用性不高

ipsvirus

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

Kristen E. Pascal, Christopher M. Coleman, Alejandro O. Mujica, Vishal Kamat, Ashok Badithe, Jeanette Fairhurst, Charleen Hunt, John Strein, Alexander Berrebi, Jeanne M. Sisk, Krystal L. Matthews, Robert Babb, Gang Chen, Ka-Man V. Lai, Tammy T. Huang, William Olson, George D. Yancopoulos, Neil Stahl, Matthew B. Frieman, and Christos A. Kyratsous

Traditional approaches to antimicrobial drug development are poorly suited to combatting the emergence of novel pathogens. Additionally, the lack of small animal models for these infections hinders the in vivo testing of potential therapeutics. Here we demonstrate the use of the VelocImmune technology (a mouse that expresses human antibody-variable heavy chains and κ light chains) alongside the VelociGene technology (which allows for rapid engineering of the mouse genome) to quickly develop and evaluate antibodies against an emerging viral disease. Specifically, we show the rapid generation of fully human neutralizing antibodies against the recently emerged Middle East Respiratory Syndrome coronavirus (MERS-CoV) and development of a humanized mouse model for MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of the isolated antibodies. The VelocImmune and VelociGene technologies are powerful platforms that can be used to rapidly respond to emerging epidemics.

http://www.pnas.org/content/earl ... 6-8567-211224357297